– CANADA, Vancouver – Wellbeing Digital Sciences Inc. (NEO: MEDI | OTC: KONEF | FRA: SQ2), an evidence-based healthcare company today announced the appointment of Najla Guthrie as its new CEO effective March 31, 2022.
About Najla Guthrie
Ms. Guthrie has been the President and CEO of KGK since 1997 and most recently also held the title of CSO for Wellbeing. Over the years, Najla has grown KGK into a leading North American contract research organization that provides high-quality clinical research trials with a focus on the nutraceutical, cannabis, and emerging psychedelic industries. Ms. Guthrie has been instrumental in publishing over 50 papers in peer-reviewed journals and has given numerous presentations at both the national and international levels. Najla is aptly fitted for her new role as CEO of Wellbeing and is highly regarded in the research, science, and leadership communities.
“It is an honor to be welcomed as the new CEO of Wellbeing. I am grateful to Adam Deffett and his hard work as Interim CEO and his positive contributions to Wellbeing since last year. I am ready to lead the Company, am optimistic for its future, and feel that we can truly make a difference in the mental health industry to help alleviate the crisis that we are facing,” said CEO, Najla Guthrie.
She added: “I am proud of the accomplishments that both KGK and IRP have announced over the last few months. They reaffirm the value of both businesses as part of Wellbeing’s greater whole, along with our joint emphasis on digital therapeutics as our third strategic pillar. I look forward to making a positive and lasting impact on the way that mental health illnesses are viewed and treated.”
About KGK Science
Founded in 1997, KGK is a leading North American contract research organization based in London, Ontario that primarily provides high-quality clinical research trials with a focus on nutraceutical and emerging health care products. The business has successfully helped hundreds of companies with custom-designed clinical trials and claim substantiation strategies to move products into global markets. KGK’s other existing service lines include expert regulatory support and compliance solutions, participant recruitment, research support services, and consulting services. On an approximate basis, the business to date has produced 150 publications, executed over 400 clinical trials across more than 40 indications, amassed 25,000 participants in its database, and collected 10 million data points.
About Wellbeing Digital Sciences
Wellbeing Digital Sciences Inc. is an evidence-based healthcare company focused on innovative clinical solutions, artificial intelligence-powered digital therapeutics, and contract research. Its mission is supported by a network of North American clinics that provide ketamine-assisted therapies and other types of treatment to patients as well as through a contract research organization that offers clinical trials services to clients pursuing drug development. In essence, the company exists to make breakthrough treatments more accessible and to offer patients transformational experiences.
For more information : https://www.wellbeingdigital.co/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
